ALL-REZ study group
ALL-REZ study group

The relapsed ALL trial group of PD Dr. med. Arend von Stackelberg

Trials on the treatment of children with relapses of acute lymphatic leukemia are done to achieve a constant improvement of diagnosis, therapy, and prognosis for affected children. In the Department for Pediatric Hematology and Oncology of the Charité theses studies are conducted by the team of PD Dr. Stackelberg.

You are here:

Clinical trials on childhood relapsed ALL in our department:

ALL-REZ BFM

Clinical Trial on the Treatment of Children with Relapses of Acute Lymphatic Leukemia (ALL)

The trial on the treatment of children with a relapse of ALL is conducted by the Society for Pediatric Oncology and Hematology (GPOH). It is also part of the Trial Group Berlin-Frankfurt-Münster made up of Pediatric Oncologic Hospitals.

Our clinic is the trial coordination center for the examination of the treatment of relapses (ALL-REZ BFM) with Prof. G. Henze acting as trial leader. For the ALL-REZ BFM 2002 trial we have been recruiting children from different hospitals all over Germany, Austria and Switzerland since 2003. These hospitals diagnose and treat the disease according to the standards set by protocol ALL-REZ BFM 2002 in order to assure a maximum of result significance for the promotion of the goals mentioned above.

Based on 25 years of experience with the treatment of relapsed ALL we continuously answer questions concerning patients with differing therapies or multiple relapses and document theese cases, to provide an individual advice on a solid database.

IntReALL

International Study for Treatment of Childhood Relapse ALL

Luckily, patient numbers have continuously decreased over the last decades due to successful treatment protocols; however, this made accrual of sufficient patient numbers more difficult. Therefore, a new international study has been started recently: The IntReALL European study for treatment of childhood ALL

IntReALL organizes the worldwide largest international clinical trial on childhood relapsed ALL for standard-risk patients and opended in summer 2014. For more information click here.